The eye warning in the GLP-1 prescribing information is easy to misread as a general alarm, and it is anything but. In the two-year trial behind it, more patients treated with the drug had complications of diabetic retinopathy than patients on placebo, and nearly the whole of that difference sat inside one group: people who already had diabetic retinopathy when the trial began. For everyone else in the trial the numbers were small and close together. A person with type 2 diabetes and existing eye disease is reading about themselves here. A person without diabetes, or without any known eye condition, is reading about a different population, and this article keeps the two apart on purpose.
What follows is the warning as the United States labels actually state it: the figures, the subgroup split that matters more than the headline, the mechanism the label names, the versions that carry no numbers at all, and the honest gap the label admits. Nothing here interprets what is happening in anyone's eyes, and nothing replaces the clinician who knows the history.
The trial behind the warning
The Ozempic label carries a section titled Diabetic Retinopathy Complications. It reports a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, in which more events of diabetic retinopathy complications occurred in patients treated with Ozempic, 3.0 percent, compared to placebo, 1.8 percent. That is the headline figure, and on its own it says little, because the same paragraph carries the split that gives the warning its shape.
The absolute risk increase was larger among patients with a history of diabetic retinopathy at baseline, 8.2 percent on Ozempic against 5.2 percent on placebo, than among patients without a known history of diabetic retinopathy, where the figures were 0.7 percent and 0.4 percent. Set those two sentences beside each other and the subject of the warning comes into focus. It is overwhelmingly about people who brought retinopathy with them into the trial, not about eyes in general, and the label is written for exactly that reader.
What the label says is behind it
Here the label is more precise than most secondhand accounts of it, and it does not name the drug as the cause. The sentence reads: rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. That association is recognized with rapid glycemic improvement generally, not only with this class of medicines, and the warning sits on these labels because these medicines can bring glucose down quickly.
Two cautions belong next to that sentence. The word temporary is the label's characterization, not a promise, and this article claims neither that the effect is harmless nor that it always resolves. And the label stops at association. It does not lay out the underlying biology in print, and this article will not fill the gap with a mechanism of its own.
GLP 1 Tracker AppDoses, side effects and notes with dates, kept privately on your phone. A dated record is what every clinician in this story, prescriber or eye specialist, can actually read.
Get the app
The same warning, label by label
Wegovy repeats the same 2-year trial in its own warnings section and adds detail the Ozempic label does not carry. The retinopathy endpoint in that trial was a 4-component adjudicated endpoint, meaning a panel reviewed potential events against defined criteria rather than each site counting its own. In a separate trial of adults with type 2 diabetes and a BMI at or above 27 treated for weight reduction, diabetic retinopathy was reported by 4 percent of Wegovy injection treated patients and 2.7 percent of placebo treated patients. And in a trial of oral semaglutide for glycemic control, moderate-severe non-proliferative diabetic retinopathy events were reported by 1.3 and 1.9 percent of patients in the 9 mg and 25 mg groups, with proliferative retinopathy events reported by 0 and 0.4 percent.
The Zepbound and Mounjaro labels carry this subject with no trial figures at all. Both read, in full, that temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control, and that patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. The two labels title the section differently, Zepbound for patients with type 2 diabetes mellitus and Mounjaro for patients with a history of diabetic retinopathy, and both sections were revised in August 2026. An absence of figures on one label is not evidence of a different risk. It reflects what each company studied and submitted.
A different eye subject entirely
GLP-1s have another eye association in public discussion, non-arteritic anterior ischemic optic neuropathy, or NAION, and the two subjects get blurred constantly. They should not be. Diabetic retinopathy is a complication of diabetes involving the small vessels at the back of the eye, and a warning about it is printed on the United States labels for these medicines. NAION is a different condition with a different population, and it appears on no US GLP-1 label. That contrast, and the split between regulators behind it, is the subject of GLP-1s and Your Eyes: Where the Regulators Disagree, and this page leaves it there.
What the label asks, and the gap it admits
The instruction in the warning is narrow: patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. That is a monitoring relationship between a patient and the clinicians who follow their eyes and their diabetes. It is not a reader's project, and it does not translate into anything this article should tell a person to arrange. Whether and when monitoring happens is a clinical decision, made by clinicians, for people with a history the trial identified.
The label also admits a gap that deserves plain statement: the effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. The figures above come from trials of defined length, and the long-run question remains open. A warning built on a two-year trial and an admitted unknown is a reason for the right people to be watched properly, not a reason for everyone to worry.
Context on the surrounding territory: what each medicine is actually approved to treat, and in which populations its trials ran, is covered at What GLP-1s Are Actually Approved to Treat, and the lab work that tends to accompany long-term treatment is covered at Blood Work on a GLP-1: Numbers Worth Keeping. Neither page is about eyes, and neither needs to be; the warning above stands on its own.
It is also worth being clear about what the warning is not. It is not a reason to prefer one product in this class over another, since the figures behind it come from one trial program and the tirzepatide labels carry the subject without figures at all. It is not a prediction about any individual's eyes, and it is not a signal that glucose should come down slowly rather than quickly; how treatment is paced is a clinical decision with many inputs, and this article adds nothing to it. It is a narrowly stated warning about a defined group of patients, and it reads best at exactly that width.
One practical note to close. If you have a history of diabetic retinopathy, the clinicians who should be watching your eyes already have a role in your care, and the most useful thing you can bring them is an accurate account of the medication story in between visits: when doses started, when they changed, what has been logged. That is a record, not a diagnosis, and keeping one is what the rest of this site is for.
Frequently asked questions
Does Ozempic cause diabetic retinopathy?
The label reports complications of existing disease in one trial, not causation in general. In a 2-year trial in patients with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications occurred in 3.0 percent of Ozempic patients versus 1.8 percent on placebo. The label associates the finding with rapid improvement in glucose control, a phenomenon recognized with rapid glycemic improvement generally, and it asks that patients with a history of diabetic retinopathy be monitored for progression.
I take a GLP-1 for weight loss and I do not have diabetes. Does this warning apply to me?
The trial behind the warning involved patients with type 2 diabetes and high cardiovascular risk, so it studied a different population from most people taking these medicines for weight management alone. Even inside that trial, patients without a known history of diabetic retinopathy had events at 0.7 percent on Ozempic against 0.4 percent on placebo, small and close together. Whether any warning applies to you personally is a question for the prescriber who knows your history.
Do Zepbound and Mounjaro carry the same retinopathy warning?
They carry the same subject with no numbers attached. Both labels state that temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control, and that patients with a history of diabetic retinopathy should be monitored for progression. Neither carries trial figures for this warning, and that absence is not evidence of a different risk; it reflects what each company studied and submitted. Both sections were revised in August 2026.
Is this the same eye concern as NAION with GLP-1s?
No, and confusing the two is the most common error in coverage of this subject. Diabetic retinopathy is a complication of diabetes involving the small vessels of the retina, and a warning about it is printed on the United States prescribing labels for these medicines. NAION, non-arteritic anterior ischemic optic neuropathy, is a different condition involving a different population, and it appears on no US GLP-1 label. The regulators disagree about NAION, and that is a separate subject.
Should I book an eye exam because I started a GLP-1?
This article gives no such instruction, because the labels give no such instruction. What the labels ask is that patients with a history of diabetic retinopathy be monitored for progression of diabetic retinopathy, which is a clinician's monitoring relationship rather than a patient project. If you have a history of retinopathy, or any change in your vision, the person to raise it with is your clinician, who decides what monitoring is right for you.